Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses

Amy S. Paller*

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Despite extensive discovery about the mutations underlying genetic skin disorders, there have been few therapeutic advances. Better understanding of the molecular changes that may lead to the phenotypic manifestations of genetic disorders may lead to the discovery of new pharmacologic interventions. The ichthyoses are characterized by scaling, inflammation, and an impaired epidermal barrier. Recent studies have uncovered T helper type 17 skewing in ichthyotic skin, resembling psoriasis, and high frequencies of IL-17– and IL-22–expressing T cells in blood, correlating with severity and transepidermal water loss. Repurposing systemic T helper type 17/IL-23–inhibitory therapies for psoriasis may prove useful for patients with ichthyosis.

Original languageEnglish (US)
Pages (from-to)535-540
Number of pages6
JournalJournal of Investigative Dermatology
Volume139
Issue number3
DOIs
StatePublished - Mar 2019

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this